Evidence map›Paper›PMID 40896556›Full record

ArticleGates open research2025

Driving innovation from discovery to access: Meeting report of the 7

Shaun Palmer, Rebecca A Clark, Bridgette J Connell, Vanessa Mwebaza Muwanga, Arthur Coelho, Paul Ogongo, Carly Young

Abstract readConference Proceedings
In one paragraph

Article in Gates open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shaun Palmer *Stichting International Aids Vaccine Initiative, Amsterdam, 1013 NH, The Netherlands.
Rebecca A Clark *London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK.
Bridgette J Connell *Stichting International Aids Vaccine Initiative, Amsterdam, 1013 NH, The Netherlands.
Vanessa Mwebaza Muwanga *Stop TB Partnership Working Group on New Vaccines, New York, NY 10004, USA.
Arthur Coelho *Universidade Federal de Goias Instituto de Patologia Tropical e Saude Publica, Goiânia, State of Goiás, 8QF3+XW, Brazil.
Paul Ogongo *University of California San Francisco Department of Medicine, San Francisco, California, 94143, USA.
Carly Young *University of Cape Town Department of Pathology, Cape Town, Western Cape, 7925, South Africa.

Funding

UCSF-UCB Tuberculosis Research Advancement Center (TRAC)P30AI168440 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JEFFERY S COX, PAYAM NAHID · 2022 to 2026
$5.8M
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigensR01AI173002 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joel D. Ernst · 2023 to 2026
$3.4M
Bill & Melinda Gates Foundation INV-001754Bill & Melinda Gates Foundation INV-039106NIAID NIH HHS P30 AI168440NIAID NIH HHS R01 AI173002
6 · The paper itself

Abstract

We urgently need novel, effective, and accessible vaccines to end tuberculosis (TB) as a public health crisis. The 7th Global Forum on TB Vaccines was convened from 8-10 October 2024 in Rio de Janeiro, Brazil. Under the theme of "Driving innovation from discovery to access," the program covered the breadth of TB vaccine research and development (R&D) through implementation, while underscoring the need for greater innovation and investments to advance development and ensure rapid, affordable, and equitable access. Participants shared the latest research on: approaches to diversify the TB vaccine pipeline, candidates advancing through late-stage trials toward licensure, and efforts to ensure new TB vaccines reach the populations that most need them. The forum provided a platform to learn from diverse experts across the field, including researchers, industry, funders, civil society, and affected communities. Participants examined cross-cutting enablers throughout, including opportunities to establish novel partnership and financing models, enhance open science, optimize R&D practices, and strengthen leadership and engagement with community members and high burden countries alike. In this report, we synthesize key themes and findings from the meeting, highlighting progress and priorities in the TB vaccine field.

Indexed as

TuberculosisTuberculosis VaccinesVaccine DevelopmentBiomedical ResearchBrazilHumansTuberculosis VaccinesAccessAdvocacyClinical trialCommunityFundingTuberculosisVaccine

Identifiers

PMID40896556
PMCPMC12391588

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.